Clinical trial
Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid…
NCT00276575 · Herbert Hurwitz, MD, Other · Completed
Key facts
| NCT number | NCT00276575 |
|---|---|
| Title | Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors |
| Official title | Phase I Study of Bevacizumab in Combination With Everolimus and Erlotinib in Advanced Cancer |
| Lead sponsor | Herbert Hurwitz, MD, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, erlotinib hydrochloride, everolimus |
| Enrollment | 65 |
| Start date | Mar 1, 2005 |
| Primary completion | Oct 1, 2012 |
| Completion | Sep 1, 2014 |
| First posted | Jan 13, 2006 |
| Last update posted | Nov 19, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: